Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Braz J Med Biol Res ; 52(7): e8303, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31291382

RESUMO

Reinforcement omission effects (ROEs) are characterized by higher response rates after reinforcement omission than after reinforcement delivery. This pattern of behavior is interpreted in terms of motivational and attentional processes. Recent studies from our laboratory have shown that the amygdala, nucleus accumbens, and medial prefrontal cortex are involved in ROE modulation. Also, the literature has demonstrated a role of other areas such as substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) in processes related to surprising events, such as prediction error and presentation or omission of an event (exteroceptive stimulus and reinforcement). Since these structures send projections to areas related to ROE modulation such as the amygdala, nucleus accumbens, and prefrontal cortex, the objective of the present study was to determine whether the SNc and VTA also integrate the circuit involved in ROE modulation. Rats were trained on a fixed-interval 12 s with limited-hold 6 s signaled schedule of reinforcement (Pre-lesion training). After acquisition of stable performance, the rats received bilateral neurotoxic lesions of the SNc (Experiment 1) and VTA (Experiment 2). Following postoperative recovery, the rats were submitted to two refresher sessions (Post-lesion training). Subsequently, the training was changed from a 100 to a 50% schedule of reinforcement (Post-lesion testing). In both experiments, the results showed that there was no difference in performance between sham rats and rats with bilateral lesions of the SNc or the VTA.


Assuntos
Comportamento Animal/fisiologia , Condicionamento Operante/fisiologia , Parte Compacta da Substância Negra/lesões , Reforço Psicológico , Substância Negra/lesões , Área Tegmentar Ventral/lesões , Animais , Aprendizagem/fisiologia , Masculino , Parte Compacta da Substância Negra/fisiopatologia , Ratos , Ratos Wistar , Substância Negra/fisiopatologia , Área Tegmentar Ventral/fisiopatologia
2.
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;52(7): e8303, 2019. graf
Artigo em Inglês | LILACS | ID: biblio-1011594

RESUMO

Reinforcement omission effects (ROEs) are characterized by higher response rates after reinforcement omission than after reinforcement delivery. This pattern of behavior is interpreted in terms of motivational and attentional processes. Recent studies from our laboratory have shown that the amygdala, nucleus accumbens, and medial prefrontal cortex are involved in ROE modulation. Also, the literature has demonstrated a role of other areas such as substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) in processes related to surprising events, such as prediction error and presentation or omission of an event (exteroceptive stimulus and reinforcement). Since these structures send projections to areas related to ROE modulation such as the amygdala, nucleus accumbens, and prefrontal cortex, the objective of the present study was to determine whether the SNc and VTA also integrate the circuit involved in ROE modulation. Rats were trained on a fixed-interval 12 s with limited-hold 6 s signaled schedule of reinforcement (Pre-lesion training). After acquisition of stable performance, the rats received bilateral neurotoxic lesions of the SNc (Experiment 1) and VTA (Experiment 2). Following postoperative recovery, the rats were submitted to two refresher sessions (Post-lesion training). Subsequently, the training was changed from a 100 to a 50% schedule of reinforcement (Post-lesion testing). In both experiments, the results showed that there was no difference in performance between sham rats and rats with bilateral lesions of the SNc or the VTA.


Assuntos
Animais , Masculino , Ratos , Reforço Psicológico , Comportamento Animal/fisiologia , Substância Negra/lesões , Área Tegmentar Ventral/lesões , Condicionamento Operante/fisiologia , Parte Compacta da Substância Negra/lesões , Substância Negra/fisiopatologia , Ratos Wistar , Área Tegmentar Ventral/fisiopatologia , Parte Compacta da Substância Negra/fisiopatologia , Aprendizagem/fisiologia
3.
Neurotox Res ; 34(4): 799-807, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29611150

RESUMO

Non-motor symptoms are increasingly identified to present clinical and diagnostic importance for Parkinson's disease (PD). The multifactorial origin of pain in PD makes this symptom of great complexity. The dopamine precursor, L-DOPA (L-3,4-dihydroxyphenylalanine), the classic therapy for PD, seems to be effective in pain threshold; however, there are no studies correlating L-DOPA-induced dyskinesia (LID) and nociception development in experimental Parkinsonism. Here, we first investigated nociceptive responses in a 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease to a hind paw-induced persistent inflammation. Further, the effect of L-DOPA on nociception behavior at different times of treatment was investigated. Pain threshold was determined using von Frey and Hot Plate/Tail Flick tests. Dyskinesia was measured by abnormal involuntary movements (AIMs) induced by L-DOPA administration. This data is consistent to show that 6-OHDA-lesioned rats had reduced nociceptive thresholds compared to non-lesioned rats. Additionally, when these rats were exposed to a persistent inflammatory challenge, we observed increased hypernociceptive responses, namely hyperalgesia. L-DOPA treatment alleviated pain responses on days 1 and 7 of treatment, but not on day 15. During that period, we observed an inverse relationship between LID and nociception threshold in these rats, with a high LID rate corresponding to a reduced nociception threshold. Interestingly, pain responses resulting from CFA-induced inflammation were significantly enhanced during established dyskinesia. These data suggest a pro-algesic effect of L-DOPA-induced dyskinesia, which is confirmed by the correlation founded here between AIMs and nociceptive indexes. In conclusion, our results are consistent with the notion that central dopaminergic mechanism is directly involved in nociceptive responses in Parkinsonism condition.


Assuntos
Antiparkinsonianos/toxicidade , Discinesia Induzida por Medicamentos/fisiopatologia , Levodopa/toxicidade , Dor Nociceptiva/fisiopatologia , Transtornos Parkinsonianos/tratamento farmacológico , Animais , Antiparkinsonianos/farmacologia , Corpo Estriado/fisiopatologia , Inflamação/fisiopatologia , Levodopa/farmacologia , Masculino , Oxidopamina , Transtornos Parkinsonianos/fisiopatologia , Parte Compacta da Substância Negra/fisiopatologia , Ratos Wistar
4.
J Biomed Sci ; 25(1): 26, 2018 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-29554962

RESUMO

BACKGROUND: Parkinson's disease is described as resulting from dopaminergic cells progressive degeneration, specifically in the substantia nigra pars compacta that influence the voluntary movements control, decision making and time perception. AIM: This review had a goal to update the relation between time perception and Parkinson's Disease. METHODOLOGY: We used the PRISMA methodology for this investigation built guided for subjects dopaminergic dysfunction in the time judgment, pharmacological models with levodopa and new studies on the time perception in Parkinson's Disease. We researched on databases Scielo, Pubmed / Medline and ISI Web of Knowledge on August 2017 and repeated in September 2017 and February 2018 using terms and associations relevant for obtaining articles in English about the aspects neurobiology incorporated in time perception. No publication status or restriction of publication date was imposed, but we used as exclusion criteria: dissertations, book reviews, conferences or editorial work. RESULTS/DISCUSSION: We have demonstrated that the time cognitive processes are underlying to performance in cognitive tasks and that many are the brain areas and functions involved and the modulators in the time perception performance. CONCLUSIONS: The influence of dopaminergic on Parkinson's Disease is an important research tool in Neuroscience while allowing for the search for clarifications regarding behavioral phenotypes of Parkinson's disease patients and to study the areas of the brain that are involved in the dopaminergic circuit and their integration with the time perception mechanisms.


Assuntos
Gânglios da Base/fisiopatologia , Doença de Parkinson/fisiopatologia , Parte Compacta da Substância Negra/fisiopatologia , Percepção do Tempo , Gânglios da Base/química , Parte Compacta da Substância Negra/química , Transmissão Sináptica/fisiologia
5.
ACS Chem Neurosci ; 8(4): 702-711, 2017 Apr 19.
Artigo em Inglês | MEDLINE | ID: mdl-28233992

RESUMO

In 1967, L-dopa was introduced as part of the pharmacological therapy of Parkinson's disease (PD) and, in spite of extensive research, no additional effective drugs have been discovered to treat PD. This brings forward the question: why have no new drugs been developed? We consider that one of the problems preventing the discovery of new drugs is that we still have no information on the pathophysiology of the neurodegeneration of the neuromelanin-containing nigrostriatal dopaminergic neurons. Currently, it is widely accepted that the degeneration of dopaminergic neurons, i.e., in the substantia nigra pars compacta, involves mitochondrial dysfunction, the formation of neurotoxic oligomers of alpha-synuclein, the dysfunction of protein degradation systems, neuroinflammation, and oxidative and endoplasmic reticulum stress. However, the initial trigger of these mechanisms in the nigrostriatal system is still unknown. It has been reported that aminochrome induces the majority of these mechanisms involved in the neurodegeneration process. Aminochrome is formed within the cytoplasm of neuromelanin-containing dopaminergic neurons during the oxidation of dopamine to neuromelanin. The oxidation of dopamine to neuromelanin is a normal and harmless process, because healthy individuals have intact neuromelanin-containing dopaminergic neurons. Interestingly, aminochrome-induced neurotoxicity is prevented by two enzymes: DT-diaphorase and glutathione transferase M2-2, which explains why melanin-containing dopaminergic neurons are intact in healthy human brains.


Assuntos
Dopamina/metabolismo , Neurônios Dopaminérgicos/patologia , Degeneração Neural/metabolismo , Doença de Parkinson/patologia , Parte Compacta da Substância Negra/patologia , Animais , Neurônios Dopaminérgicos/metabolismo , Humanos , Melaninas/metabolismo , Degeneração Neural/fisiopatologia , Oxirredução , Doença de Parkinson/metabolismo , Doença de Parkinson/fisiopatologia , Parte Compacta da Substância Negra/metabolismo , Parte Compacta da Substância Negra/fisiopatologia
6.
Arq Neuropsiquiatr ; 73(7): 616-23, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26200058

RESUMO

Parkinson's disease (PD) is the second most common neurodegenerative disease affecting approximately 1.6% of the population over 60 years old. The cardinal motor symptoms are the result of progressive degeneration of substantia nigra pars compacta dopaminergic neurons which are involved in the fine motor control. Currently, there is no cure for this pathology and the cause of the neurodegeneration remains unknown. Several studies suggest the involvement of neuroinflammation in the pathophysiology of PD as well as a protective effect of anti-inflammatory drugs both in animal models and epidemiological studies, although there are controversial reports. In this review, we address evidences of involvement of inflammatory process and possible therapeutic usefulness of anti-inflammatory drugs in PD.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Encefalite/tratamento farmacológico , Encefalite/fisiopatologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Citocinas , Humanos , Degeneração Neural/tratamento farmacológico , Degeneração Neural/fisiopatologia , Doença de Parkinson/etiologia , Parte Compacta da Substância Negra/fisiopatologia , Reprodutibilidade dos Testes , Fatores de Risco , Resultado do Tratamento
7.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;73(7): 616-623, 07/2015. tab
Artigo em Inglês | LILACS | ID: lil-752381

RESUMO

Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting approximately 1.6% of the population over 60 years old. The cardinal motor symptoms are the result of progressive degeneration of substantia nigra pars compacta dopaminergic neurons which are involved in the fine motor control. Currently, there is no cure for this pathology and the cause of the neurodegeneration remains unknown. Several studies suggest the involvement of neuroinflammation in the pathophysiology of PD as well as a protective effect of anti-inflammatory drugs both in animal models and epidemiological studies, although there are controversial reports. In this review, we address evidences of involvement of inflammatory process and possible therapeutic usefulness of anti-inflammatory drugs in PD.


A doença de Parkinson (DP) é a segunda doença neurodegenerativa mais comum afetando aproximadamente 1,6% da população acima de 60 anos de idade. Os sinais motores cardinais são o resultado da degeneração progressiva de neurônios dopaminérgicos da substantia nigra pars compacta (SNpc), a qual está intimamente envolvida com o controle motor. Atualmente, não há cura para esta patologia e a causa da neurodegeneração permanece desconhecida. Contudo, muitos estudos sugerem o envolvimento da neuroinflamação na patofisiologia da DP bem como um efeito protetor de drogas antiinflamatórias tanto em modelos animais quanto em estudos epidemiológicos, embora haja relatos controversos. Nesta revisão, foram abordadas evidências de envolvimento do processo inflamatório e uma possível utilidade terapêutica de drogas antiinflamatórias na DP.


Assuntos
Animais , Humanos , Anti-Inflamatórios não Esteroides/uso terapêutico , Encefalite/tratamento farmacológico , Encefalite/fisiopatologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/fisiopatologia , Anti-Inflamatórios não Esteroides/farmacologia , Citocinas , Degeneração Neural/tratamento farmacológico , Degeneração Neural/fisiopatologia , Doença de Parkinson/etiologia , Parte Compacta da Substância Negra/fisiopatologia , Reprodutibilidade dos Testes , Fatores de Risco , Resultado do Tratamento
8.
Brain Res ; 1593: 95-105, 2014 Dec 17.
Artigo em Inglês | MEDLINE | ID: mdl-25301688

RESUMO

Parkinson׳s disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Systemic and intranigral exposure to rotenone in rodents reproduces many of the pathological and behavioral features of PD in humans and thus has been used as an animal model of the disease. Melatonin is a neurohormone secreted by the pineal gland, which has several important physiological functions. It has been reported to be neuroprotective in some animal models of PD. The present study investigated the effects of prolonged melatonin treatment in rats previously exposed to rotenone. The animals were intraperitoneally treated for 10 days with rotenone (2.5mg/kg) or its vehicle. 24h later, they were intraperitoneally treated with melatonin (10mg/kg) or its vehicle for 28 days. One day after the last rotenone exposure, the animals exhibited hypolocomotion in the open field test, which spontaneously reversed at the last motor evaluation. We verified that prolonged melatonin treatment after dopaminergic lesion did not alter motor function but produced antidepressant-like effects in the forced swim test, prevented the rotenone-induced reduction of striatal dopamine, and partially prevented tyrosine hydroxylase immunoreactivity loss in the SNpc. Our results indicate that melatonin exerts neuroprotective and antidepressant-like effects in the rotenone model of PD.


Assuntos
Antidepressivos/administração & dosagem , Melatonina/administração & dosagem , Fármacos Neuroprotetores/administração & dosagem , Transtornos Parkinsonianos/tratamento farmacológico , Animais , Corpo Estriado/efeitos dos fármacos , Corpo Estriado/patologia , Corpo Estriado/fisiopatologia , Dopamina/metabolismo , Masculino , Atividade Motora/efeitos dos fármacos , Norepinefrina/metabolismo , Transtornos Parkinsonianos/patologia , Transtornos Parkinsonianos/fisiopatologia , Parte Compacta da Substância Negra/efeitos dos fármacos , Parte Compacta da Substância Negra/patologia , Parte Compacta da Substância Negra/fisiopatologia , Distribuição Aleatória , Ratos Wistar , Rotenona , Serotonina/metabolismo , Tirosina 3-Mono-Oxigenase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA